Literature DB >> 26236760

Update on biomarkers in neuromyelitis optica.

Esther Melamed1, Michael Levy1, Patrick J Waters1, Douglas Kazutoshi Sato1, Jeffrey L Bennett1, Gareth R John1, Douglas C Hooper1, Albert Saiz1, Amit Bar-Or1, Ho Jin Kim1, Lakha Pandit1, Maria Isabel Leite1, Nasrin Asgari1, Najib Kissani1, Rogier Hintzen1, Romain Marignier1, Sven Jarius1, John Marcelletti1, Terry J Smith1, Michael R Yeaman1, May H Han1, Orhan Aktas, Metha Apiwattanakul, Brenda Banwell, Denis Bichuetti, Simon Broadley, Philippe Cabre, Tanuja Chitnis, Jerome De Seze, Kazuo Fujihara, Benjamin Greenberg, Kerstin Hellwig, Raffaele Iorio, Sven Jarius1, Eric Klawiter, Ingo Kleiter, Marco Lana-Peixoto, Kevin O'Connor, Jacqueline Palace, Friedman Paul, Naraporn Prayoonwiwat, Klemens Ruprecht, Olaf Stuve, Thomas Tedder, Silvia Tenembaum, Juan P Garrahan, Buenos Aires, Katja van Herle, Danielle van Pelt, Pablo Villoslada, Emmanuelle Waubant, Brian Weinshenker, Dean Wingerchuk, Jens Würfel, Scott Zamvil.   

Abstract

Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

Entities:  

Year:  2015        PMID： 26236760      PMCID： PMC4516398          DOI： 10.1212/NXI.0000000000000134

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN： 2332-7812


  57 in total

1.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  NMO-IgG in the diagnosis of neuromyelitis optica.

Authors:  S Jarius; D Franciotta; R Bergamaschi; H Wright; E Littleton; J Palace; R Hohlfeld; A Vincent
Journal:  Neurology       Date:  2007-02-07       Impact factor: 9.910

3.  Molecular structure of the water channel through aquaporin CHIP. The hourglass model.

Authors:  J S Jung; G M Preston; B L Smith; W B Guggino; P Agre
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

4.  Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats.

Authors:  C Brunner; H Lassmann; T V Waehneldt; J M Matthieu; C Linington
Journal:  J Neurochem       Date:  1989-01       Impact factor: 5.372

5.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

6.  Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.

Authors:  S Watanabe; I Nakashima; T Misu; I Miyazawa; Y Shiga; K Fujihara; Y Itoyama
Journal:  Mult Scler       Date:  2007-01       Impact factor: 6.312

7.  Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution.

Authors:  Elisa Bizzoco; Francesco Lolli; Anna Maria Repice; Bahia Hakiki; Mario Falcini; Alessandro Barilaro; Rosanna Taiuti; Gianfranco Siracusa; Maria Pia Amato; Tiziana Biagioli; Silvia Lori; Marco Moretti; Annalisa Vinattieri; Patrizia Nencini; Luca Massacesi; Sabrina Matà
Journal:  J Neurol       Date:  2009-05-28       Impact factor: 4.849

Review 8.  Aquaporin-4 in brain and spinal cord oedema.

Authors:  S Saadoun; M C Papadopoulos
Journal:  Neuroscience       Date:  2009-08-12       Impact factor: 3.590

9.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Authors:  Hua Zhang; A S Verkman
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307
View more
  32 in total

1.  Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.

Authors:  Jia Liu; Li Xu; Zhuo-Lin Chen; Min Li; Huan Yi; Fu-Hua Peng
Journal:  Bosn J Basic Med Sci       Date:  2018-02-20       Impact factor: 3.363

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 3.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

Review 4.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

5.  Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.

Authors:  Maureen A Mealy; Su-Hyun Kim; Felix Schmidt; Reydmar López; Jorge A Jimenez Arango; Friedemann Paul; Dean M Wingerchuk; Benjamin M Greenberg; Ho Jin Kim; Michael Levy
Journal:  Mult Scler       Date:  2017-08-31       Impact factor: 6.312

Review 6.  Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.

Authors:  Joseph Kuchling; Alexander U Brandt; Friedemann Paul; Michael Scheel
Journal:  EPMA J       Date:  2017-07-25       Impact factor: 6.543

7.  Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Authors:  Itay Lotan; Richard McGowan; Michael Levy
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 8.  A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Authors:  Jacqueline M Solomon; Friedemann Paul; Claudia Chien; Jiwon Oh; Dalia L Rotstein
Journal:  Ther Adv Neurol Disord       Date:  2021-05-09       Impact factor: 6.570

Review 9.  Update on pediatric optic neuritis.

Authors:  Jane H Lock; Nancy J Newman; Valérie Biousse; Jason H Peragallo
Journal:  Curr Opin Ophthalmol       Date:  2019-11       Impact factor: 3.761

10.  Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder.

Authors:  Jie Li; Sam A Bazzi; Florian Schmitz; Hidetaka Tanno; Jonathan R McDaniel; Chang-Han Lee; Chaitanya Joshi; Jin Eyun Kim; Nancy Monson; Benjamin M Greenberg; Kristina Hedfalk; Esther Melamed; Gregory C Ippolito
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.